MDA-MB-468
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
MDA-MB-468 |
Humane Brust Karzinom Zell-Linie |
300279 |
cryovial |
265,00 |
MDA-MB-468 |
Humane Brust Karzinom Zell-Linie |
330279 |
vital |
335,00 |
| Designation: | MDA-MB-468 |
| Organism: | Homo sapiens (human) |
| Ethnicity: | black |
| Age/Stage: | 51 years old |
| Gender: | female |
| Tissue: | Breast; mammary gland |
| Morphology: | epithelial |
| Celltype: | adenocarcinoma |
| Growth Properties: | monolayer |
| Description: | Although the tissue donor was heterozygous for the G6PD alleles, the cell line consistently showed only the G6PD A phenotype. There is a G -> A mutation in codon 273 of the p53 gene resulting in an Arg -> His substitution. |
| Culture Medium: | DMEM:Ham's-F12 medium (1:1, vol/vol) supplemented with 2 mM L-glutamine and 10% fetal bovine serum. |
| Subculturing: | Remove medium, rinse with fresh 0.25% trypsin, 0.02% EDTA solution, remove trypsin and let the culture sit at room temperature (or at 37°C) until the cells detach. Add fresh medium, aspirate and dispense into new flasks. Incubate at 37°C / 5% CO2. |
| Split Ratio: | A ratio of 1:2 to 1:4 is recommended |
| Fluid Renewal: | 2 to 3 times weekly |
| Freeze Medium: | CM-1 (CLS ∙ Cell Lines Service) |
| Sterility: | Tests for mycoplasma, bacteria and fungi were negative |
| Biosafety Level: | 1 |
| Tumorigenic: | yes, in nude mice |
| Karyotype: | predominantly hypodiploid with a minor bimodal component having about 70 chromosomes |
| DNA Profile (STR): | Amelogenin: X,X CSF1PO: 12 D13S317: 12 D16S539: 9 D5S818: 12 D7S820: 8 TH01: 7 TPOX: 8,9 vWA: 18 D3S1358: 15 D21S11: 27,28 D18S51: 17 Penta E: 5 Penta D: 8,10 D8S1179: 13 FGA: 23 CLS – Cell Lines Service 2010. |
| Antigen Expression: | Blood Type AB; HLA Aw23, Aw30, B27, Bw35, Cw2, Cw4 (patient) |
| Receptors Expressed: | EGF (epidermal growth factor) receptor is present at 1 x 106 per cell; transforming growth factor alpha (TGF alpha) |
| Isoenzymes: | G6PD, A; PGM1, 1; PGM3, 2; ES-D, 1; Me-2, 1-2; AK-1, 1; GLO-1, 1-2; Phenotype Frequency Product: 0.0020 |
References: Cailleau R et al. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14: 911-5, 1978. Siciliano MJ et al. Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker. Cancer Res 39: 919-22, 1979. Pathak S et al. A human breast adenocarcinoma with chromosome and isoenzyme markers similar to those of the HeLa line. J Natl Cancer Inst 62: 263-71, 1979. Brinkley BR et al. Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res 40: 3118-29, 1980. Nigro JM et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-7, 1989. Bates SE et al. Expression of the transforming growth factor-alpha/epidermal growth factor receptor pathway in normal human breast epithelial cells. Endocrinology 126: 596-607, 1990. Avila MA et al. Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468. Cancer Res 54: 2424-8, 1994. Zamora-Leon SP et al. Expression of the fructose transporter GLUT5 in human breast cancer. Proc Natl Acad Sci USA 93: 1847-52, 1996. Littlewood-Evans AJ et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 57:5386-90, 1997. Pervin et al. Nitric-Oxide-Induced Bax integration into the mitochondrial membrane commits MDA-MB-468 cells into apoptosis: Essential role of Act. Cancer Res 63: 5470-5479, 2003. Hu M et al. HIV-1 tat peptide immunoconjugates differentially sensitize breast cancer cells to select antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21(WAF-1/CIP-1). Bioconjug Chem 17: 1280-7, 2006. Jones DT et al. Novel Thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-{alpha} expression but decrease functional transcriptional activity, DNA binding, and Degradation. Clin Cancer Res 12: 5384-94, 2006. | |
